ApprovalApr 21, 2026
FDA approval — Merck Weighs New HIV Approval Against Mixed Oncology Trial Results▸
high impact
FilingApr 20, 2026
Regulatory filing — FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-p…▸
medium impact
FilingApr 17, 2026
Regulatory filing — Merck’s Priority Review Cancer Drug Adds To Undervalued Growth Story▸
medium impact
FilingApr 13, 2026
Regulatory filing — Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Sm…▸
medium impact
DealApr 07, 2026
Deal — Merck’s Terns Deal Targets Cancer Pipeline And Keytruda Patent Risks▸
medium impact
Data +Apr 02, 2026
Positive data — Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9▸
high impact
DealMar 28, 2026
Deal — Merck & Co. (MRK) to Acquire Terns Pharma for $6.7 Billion▸
medium impact
ApprovalMar 27, 2026
FDA approval — Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx▸
high impact
DealMar 27, 2026
Deal — Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition▸
medium impact
DealMar 25, 2026
Deal — Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business▸
medium impact
EarningsFeb 03, 2026
FY 2025 report+5.3%positive
EarningsOct 30, 2025
Q3 2025 report-2.8%muted
EarningsJul 25, 2025
Q2 2025 report-3.5%negative
EarningsApr 24, 2025
Q1 2025 report+6.1%positive
EarningsFeb 04, 2025
FY 2024 report-3.8%negative
EarningsOct 31, 2024
Q3 2024 report-0.7%muted
EarningsJul 30, 2024
Q2 2024 report-0.0%muted
EarningsApr 25, 2024
Q1 2024 report-1.2%muted